Burning Rock Biotech (NASDAQ:BNR) Posts Quarterly Earnings Results, Beats Estimates By $2.04 EPS

Burning Rock Biotech (NASDAQ:BNR) issued its earnings results on Tuesday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.29) by $2.04, FiscalAI reports. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.89%. The firm had revenue of $15.66 million for the quarter, compared to analysts’ expectations of $19.21 million.

Burning Rock Biotech Stock Performance

Shares of Burning Rock Biotech stock opened at $8.33 on Thursday. The stock has a market capitalization of $87.61 million, a price-to-earnings ratio of -10.16 and a beta of 1.32. The company’s 50 day moving average price is $15.74 and its 200-day moving average price is $21.24. Burning Rock Biotech has a 52-week low of $2.95 and a 52-week high of $41.72.

Insiders Place Their Bets

In related news, Director Yusheng Han purchased 314,870 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The shares were acquired at an average price of $17.36 per share, for a total transaction of $5,466,143.20. Following the completion of the acquisition, the director directly owned 17,672,676 shares in the company, valued at approximately $306,797,655.36. The trade was a 1.81% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 30.30% of the stock is currently owned by company insiders.

Institutional Trading of Burning Rock Biotech

An institutional investor recently bought a new position in Burning Rock Biotech stock. Marshall Wace LLP purchased a new stake in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 10,903 shares of the company’s stock, valued at approximately $220,000. Marshall Wace LLP owned approximately 0.10% of Burning Rock Biotech as of its most recent SEC filing. Institutional investors and hedge funds own 30.03% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Burning Rock Biotech currently has a consensus rating of “Sell”.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.